Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment

Daiichi Sankyo in March started a clinical trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients. The company said in a statement it was discontinuing the trial without citing a reason. The Nikkei newspaper reported that there were safety concerns. Nafamostat is used in the treatment of pancreatitis and has antiviral properties.

Reuters | Tokyo | Updated: 15-06-2021 12:45 IST | Created: 15-06-2021 12:36 IST

Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment — Image Credit: ANI

Country:
Japan

Japan's Daiichi Sankyo Co said on Tuesday it was halting development of an existing drug for the treatment of COVID-19. Daiichi Sankyo in March started a clinical trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients. The company said in a statement it was discontinuing the trial without citing a reason. The Nikkei newspaper reported that there were safety concerns.

Nafamostat is used in the treatment of pancreatitis and has antiviral properties.

Also Read: Olympics-Japan considers asking Olympic fans for negative COVID tests, vaccinations - Yomiuri

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)